US Patent 11873279 Compositions for treatment of ocular diseases
Patent 11873279 was granted and assigned to Perfuse Therapeutics, Inc. on January, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 19 Jan, 2024
Golden AI
Edits made to:
Infobox (+20 properties)
Article (+520 characters)
US Patent 11873279 Compositions for treatment of ocular diseases
Article
Patent abstract
The present disclosure relates to the discovery that certain ocular diseases may be treated using Edonentan crystalline forms. Specific Edonentan crystalline form can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, or an anti-VEGF agent. Using Edonentan crystalline forms, alone or in combination with an additional agent, provides increased perfusion to the retina or reduced IOP in certain ocular diseases and reduces damage to retinal cells.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
David Floyd0
Sevgi Gurkan0
Zhongli Ding0
Date of Patent
January 16, 2024
0Patent Application Number
178796270
Date Filed
August 2, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11873279 Compositions for treatment of ocular diseases
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
